BDTX Stock Analysis: Black Diamond Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 115m USD | 12M Return: -16.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.48M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Black Diamond Therapeutics (NASDAQ: BDTX) is a clinical-stage oncology company headquartered in Cambridge, Massachusetts, focused on developing MasterKey therapies designed to address genetically defined tumors regardless of cancer type. Its lead candidate, silevertinib, is a brain-penetrant EGFR inhibitor currently in Phase 2 trials for EGFR-mutant non-small cell lung cancer and glioblastoma. The pipeline also includes BDTX-4933, a brain-penetrant RAF inhibitor in Phase 1 development for KRAS, NRAS, and BRAF-altered solid tumors, and BDTX-4876, a FGFR2/3-selective inhibitor in preclinical stage. The company was incorporated in 2014 (originally as ASET Therapeutics) and trades as a micro-cap stock in the biotechnology sub-industry.
As a clinical-stage biotech with no approved or commercialized products, Black Diamonds business model is centered on advancing early- and mid-stage R&D, with funding typically sourced from capital markets and partnership deals rather than product revenue. Its MasterKey approach represents a mutation-agnostic strategy that contrasts with traditional tumor-type-specific drug development, aiming to treat cancers driven by specific oncogenic alterations such as EGFR and KRAS mutations, which are among the most prevalent drivers in lung cancer.
- Silevertinib Phase 2 NSCLC data readout
- BDTX-4933 Phase 1 KRAS solid tumor results
- Cash runway narrows amid clinical spending
| Net Income: -43.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.26 > 0.02 and ΔFCF/TA -32.58 > 1.0 |
| NWC/Revenue: 154.9% < 20% (prev 196.9%; Δ -41.98% < -1%) |
| CFO/TA -0.26 > 3% & CFO -34.0m > Net Income -43.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.46 > 1.5 & < 3 |
| Outstanding Shares: last quarter (57.2m) vs 12m ago -0.76% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 45.28% > 50% (prev 40.01%; Δ 5.27% > 0%) |
| Interest Coverage Ratio: -7.90 > 6 (EBIT TTM -38.4m / Interest Expense TTM 4.85m) |
| A: 0.82 (Total Current Assets 123.0m - Total Current Liabilities 14.5m) / Total Assets 132.9m |
| B: -3.56 (Retained Earnings -473.8m / Total Assets 132.9m) |
| C: -0.25 (EBIT TTM -38.4m / Avg Total Assets 154.6m) |
| D: 3.64 (Book Value of Equity 104.3m / Total Liabilities 28.6m) |
| Altman-Z'' = -4.11 = D |
As of July 08, 2026, the stock is trading at USD 2.08 with a total of 2,199,075 shares traded. Over the past week, the price has changed by +18.86%, over one month by +12.43%, over three months by -15.10% and over the past year by -16.80%.
Current recommended Stop Loss: 1.80 (which is 13.5% or 1.6 ATR below the current price).
Black Diamond Therapeutics has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy BDTX.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 9.9 | 374% |
P/E Forward = 8.3333
P/S = 2.112
P/B = 1.1098
Revenue TTM = 70.0m USD
EBIT TTM = -38.4m USD
EBITDA TTM = -38.1m USD
Long Term Debt = 14.1m USD (estimated: total debt 17.9m - short term 3.79m)
Short Term Debt = 3.79m USD (from shortTermDebt, last quarter)
Debt = 17.9m USD (from shortLongTermDebtTotal, last quarter) (leases 17.9m already included)
Net Debt = -100.4m USD (calculated: Debt 17.9m - CCE 118.3m)
Enterprise Value = 14.8m USD (115.2m + Debt 17.9m - CCE 118.3m)
Interest Coverage Ratio = -7.90 (Ebit TTM -38.4m / Interest Expense TTM 4.85m)
EV/FCF = -0.43x (Enterprise Value 14.8m / FCF TTM -34.0m)
FCF Yield = -229.9% (FCF TTM -34.0m / Enterprise Value 14.8m)
FCF Margin = -48.61% (FCF TTM -34.0m / Revenue TTM 70.0m)
Net Margin = -61.73% (Net Income TTM -43.2m / Revenue TTM 70.0m)
Gross Margin = unknown ((Revenue TTM 70.0m - Cost of Revenue TTM 325k) / Revenue TTM)
Tobins Q-Ratio = 0.11 (Enterprise Value 14.8m / Total Assets 132.9m)
Interest Expense / Debt = 27.14% (Interest Expense 4.85m / Debt 17.9m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -30.3m (EBIT -38.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.46 (Total Current Assets 123.0m / Total Current Liabilities 14.5m)
Debt / Equity = 0.17 (Debt 17.9m / totalStockholderEquity, last quarter 104.3m)
Debt / EBITDA = 2.64 (negative EBITDA) (Net Debt -100.4m / EBITDA -38.1m)
Debt / FCF = 2.95 (negative FCF - burning cash) (Net Debt -100.4m / FCF TTM -34.0m)
Total Stockholder Equity = 118.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -27.95% (Net Income -43.2m / Total Assets 132.9m)
RoE = -36.37% (Net Income TTM -43.2m / Total Stockholder Equity 118.8m)
RoCE = -28.86% (EBIT -38.4m / Capital Employed (Equity 118.8m + L.T.Debt 14.1m))
RoIC = -25.53% (negative operating profit) (NOPAT -30.3m / Invested Capital 118.7m)
WACC = 16.02% (E(115.2m)/V(133.1m) * Re(15.18%) + D(17.9m)/V(133.1m) * Rd(27.14%) * (1-Tc(0.21)))
Discount Rate = 15.18% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 82.22 | Cagr: 8.69%
[DCF] Fair Price = unknown (Cash Flow -34.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.31 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.20 | Chg30d=+6.54% | Revisions=+17% | Analysts=6
EPS next Quarter (2026-09-30): EPS=-0.06 | Chg30d=-30.43% | Revisions=+17% | Analysts=6
EPS current Year (2026-12-31): EPS=-0.63 | Chg30d=+1.08% | Revisions=-12% | GrowthEPS=-222.4% | GrowthRev=-92.1%
EPS next Year (2027-12-31): EPS=-1.16 | Chg30d=-12.60% | Revisions=+0% | GrowthEPS=-84.0% | GrowthRev=-100.0%
[Analyst] Revisions Ratio: +6% (up=8, down=7)